Oncotarget

Reviews:

Role of PLZF as a tumor suppressor in prostate cancer

Yang Jin _, Hatice Zeynep Nenseth and Fahri Saatcioglu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:71317-71324. https://doi.org/10.18632/oncotarget.19813

Metrics: PDF 912 views  |   HTML 2051 views  |   ?  


Abstract

Yang Jin1, Hatice Zeynep Nenseth2 and Fahri Saatcioglu1,2

1Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

2Department of Biosciences, University of Oslo, Oslo, Norway

Correspondence to:

Yang Jin, email: yangj@ibv.uio.no

Fahri Saatcioglu, email: fahris@ibv.uio.no

Keywords: promyelocytic leukemia zinc finger, prostate cancer, tumor suppressor, androgens

Received: March 16, 2017     Accepted: July 12, 2017     Published: August 02, 2017

ABSTRACT

The promyelocytic leukemia zinc finger (PLZF), also known as ZBTB16 (Zinc Finger And BTB Domain Containing 16), is a transcription factor involved in the regulation of diverse biological processes, including cell proliferation, differentiation, organ development, stem cell maintenance and innate immune cell development. A number of recent studies have now implicated PLZF in cancer progression as a tumor suppressor. However, in certain cancer types, PLZF may function as an oncoprotein. Here, we summarize our current knowledge on the role of PLZF in various cancer types, in particular prostate cancer, including its deregulation, genomic alterations and potential functions in prostate cancer progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19813